Rosenstock J, et al. - In patients with type 2 diabetes, researchers assessed the effectiveness and long-term adverse-event profiles of once-daily oral semaglutide vs sitagliptin 100 mg added on to metformin with or without sulfonylurea. Participants in the study were randomized to receive once-daily oral semaglutide 3 mg (n=466), 7 mg (n=466), or 14 mg (n=465), or sitagliptin 100 mg (n=467). Semaglutide was initiated at 3 mg/d and increased every 4 weeks—first to 7 mg/d and then to 14 mg/d—until the randomized dose was reached. A total of 1,758 participants completed the trial, and 298 prematurely discontinued treatment among 1,864 randomized patients. According to findings, when added to metformin with or without sulfonylurea, oral semaglutide 7 mg/d and 14 mg/d resulted in higher glycated hemoglobin improvements than sitagliptin after 26 weeks. Compared with sitagliptin, there was no significant benefit with 3 mg/d oral semaglutide.